PTC Therapeutics, Inc. — Q2 2015 Form 10-Q
Business context and reporting period. This unaudited quarterly report covers the three and six months ended June 30, 2015. PTC is a biopharmaceutical company developing small-molecule therapies; its lead product, Translarna (ataluren), had conditional European authorization for nonsense-mutation Duchenne muscular dystrophy (nmDMD) and was being launched in selected markets. The company remained in a substantial investment and operating-loss phase.
Financial results and liquidity
| Metric | Q2 2015 | Q2 2014 | Six months 2015 | Six months 2014 |
|---|---|---|---|---|
| Total revenue | $6.8m | $1.7m | $14.3m | $10.9m |
| Net product revenue | $6.2m | — | $11.2m | — |
| Research and development | $28.2m | $18.3m | $56.1m | $34.2m |
| Selling, general and administrative | $17.2m | $8.7m | $34.8m | $16.3m |
| Operating loss | $38.6m | $25.4m | $76.7m | $39.6m |
| Net loss | $38.4m | $25.1m | $76.3m | $39.2m |
| Basic and diluted loss per share | $1.14 | $0.86 | $2.29 | $1.40 |
- For the six months, operating cash use was $66.2m, compared with $32.2m a year earlier. Investing activities provided $37.3m, principally from marketable-security sales and maturities; financing provided $8.1m, largely from option exercises. Cash and cash equivalents declined $20.5m to $29.2m.
- At June 30, cash, cash equivalents and marketable securities totaled $255.2m. Current assets were $264.6m and current liabilities $23.1m, implying working capital of approximately $241.5m. Total liabilities were $25.2m; the filing reports no outstanding long-term debt balance.
- Gross margin is not clearly presented: product manufacturing costs were principally royalties of less than $0.1m and were recorded in R&D, and PTC had not capitalized inventory.
Material changes versus prior periods
- Product sales began contributing materially to revenue: Q2 net product revenue was $6.2m, versus none in Q2 2014. H1 2015 product revenue was $11.2m, including $1.4m from 2014 sales deferred under the prior cash-basis recognition approach; beginning in 2015, revenue was recognized upon shipment after PTC established a collection history.
- H1 total revenue rose about 31%, but collaboration and grant revenue fell $7.9m to $3.0m, mainly because the prior-year period included a nonrecurring $7.5m Roche milestone.
- H1 R&D increased 64% and SG&A increased 114%, reflecting clinical development, pipeline expansion and commercial-launch investment, as well as higher share-based compensation. Net loss widened to $76.3m from $39.2m.
Outlook, commentary and key risks
- Management expected available cash, cash equivalents, marketable securities and anticipated collaboration research funding to fund operating and capital needs through late 2017. This estimate depends on assumptions and could prove too optimistic; PTC expected significant losses and expenses for at least several years and may need additional financing.
- PTC expected 2015 revenue mainly from Translarna sales in EEA countries where acceptable pricing and reimbursement could be secured and from reimbursed early-access programs. It planned to expand launches, but country-level market access can take more than 18 months; management noted that pricing and reimbursement remained a significant uncertainty.
- PTC expected ACT DMD top-line results in Q4 2015. The EEA authorization was conditional, subject to annual EMA review, and tied to completing ACT DMD and submitting the final report during 2015. Adverse trial results or failure to meet conditions could jeopardize authorization.
- ACT CF enrollment was expected to finish by year-end 2015, with top-line results about a year later. PTC planned to seek an EEA label variation for nmCF in the second half of 2015, but acknowledged substantial approval risk and potential differences with FDA views on trial design.
- RG7800, PTC’s SMA collaboration candidate, was generally tolerated in the first Phase 2 cohort, but dosing was suspended in April 2015 after a 39-week monkey toxicology study identified an eye finding at exposures above those explored in people. Further preclinical data were expected in Q4; dosing might resume in Q1 2016, subject to those findings.
- Other pipeline activity included a Phase 1 study of PTC596, initiated in April 2015, and IND-enabling studies for antibacterial candidate PTC672. Management also described exploratory Translarna programs for MPS I and aniridia. Retrospective cystic-fibrosis subgroup findings were not confirmatory trial results.
- Other notable risks include limited commercial-launch experience; restricted eligible patient populations; uncertain reimbursement, demand and product acceptance; clinical, regulatory and safety uncertainty; reliance on third-party manufacturers and distributors; and potential additional capital needs and shareholder dilution. No material legal proceedings or material changes to contractual obligations or market-risk disclosures were reported. Management concluded disclosure controls were effective as of June 30, 2015.
Important facts for investors to verify
- ACT DMD top-line timing and results, and compliance with the conditional EEA authorization requirements.
- Translarna country-level sales, collection, pricing and reimbursement progress, including the implications of the change in revenue-recognition timing.
- Cash burn relative to management’s late-2017 funding estimate and any need for additional capital.
- ACT CF progress and the regulatory pathway for nmCF, including the evidentiary limits of retrospective subgroup analyses.
- RG7800 follow-up safety findings and whether the MOONFISH study can resume.